16
total announcements
BROOKS.NS · 15 min delayed
Brooks Laboratories Limited
Brooks Laboratories Limited has published an addendum to the notice of its 24th Annual General Meeting, which will be held on September 3rd. The addendum was published in two newspapers, Financial Express and Jansatta, on August 22nd.
Brooks Laboratories Limited
Brooks Laboratories Limited has issued an addendum to the notice of its 24th Annual General Meeting, scheduled to be held on September 3, 2026, to inform shareholders of changes in Resolution No. 4 and its explanatory statement regarding a corporate guarantee arrangement.
Brooks Laboratories Limited
Brooks Laboratories Limited has informed the Exchange regarding 'Intimation Of Record Date, E-Voting Dates And Book Closure Date'. The company has announced the record date, e-voting dates, and book closure date for its 24th Annual General Meeting. The book closure period will be from August 27, 2026, to September 3, 2026, and the e-voting period will be from August 31, 2026, to September 2, 2026.
Brooks Laboratories Limited
Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Brooks Laboratories Limited
Brooks Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 141.86 lakhs and a loss of Rs. 178.69 lakhs for the standalone and consolidated entities respectively.
Brooks Laboratories Limited
Brooks Laboratories Limited has announced the 24th Annual General Meeting (AGM) to be held on September 3, 2026, through Video Conference/Other Audio-Visual Means.
Brooks Laboratories Limited
Brooks Laboratories Limited has announced the 24th Annual General Meeting (AGM) and Annual Report for the FY 2025-26. The AGM will be held on September 3, 2026, through video conferencing. The company has also sent a letter to shareholders who have not registered their email addresses, providing a web-link to access the Annual Report.
Brooks Laboratories Limited
Brooks Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 03, 2026.
Brooks Laboratories Limited
Brooks Laboratories Limited has intimated the 24th Annual General Meeting through a newspaper publication, to be held on 3rd September 2026 through Video Conference (VC)/Other Audio-Visual Means (OAVM).
Brooks Laboratories Limited
Brooks Laboratories Limited has appointed Mr. Rajesh Mahajan as President - Trading with effect from July 17, 2026.
Brooks Laboratories Limited
Brooks Laboratories Limited has entered into a binding Memorandum of Understanding (MoU) with Steriscience Specialties Private Limited and Brooks Steriscience Limited. The MoU records the commercial understanding among the parties in relation to the Company's proposed continuing investment in Brooks Steriscience Limited upon completion of the transaction. The MoU provides a value protection framework in respect of the Company's remaining investment, anti-dilution rights in respect of the existing business, principles governing capital requirements for the existing and future business lines, and certain interim rights and obligations of the parties during the term of the MoU.
Brooks Laboratories Limited
Brooks Laboratories Limited has received a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th June 2026. The certificate confirms that securities received from depository participants for dematerialisation were confirmed and listed on stock exchanges.
Brooks Laboratories Limited
Brooks Laboratories Limited has incorporated a wholly owned subsidiary, Abridge Speciality Limited, to expand its business.
Brooks Laboratories Limited
Brooks Laboratories Limited announced the closure of its trading window for Designated Persons and their immediate relatives, effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting and the opening of the trading window will be communicated later.
Brooks Laboratories Limited
Brooks Laboratories Limited announced it received a request from BSE Limited for additional details regarding its previously disclosed "Partial Sale of Equity Shares Held in Brooks Steriscience Limited" on June 19, 2026. The exchange specifically sought the Board Meeting commencement and conclusion times related to that transaction, in compliance with SEBI regulations. The company is submitting a revised disclosure to provide these required details. For investors, this update signifies regulatory scrutiny of the company's significant transaction and Brooks Laboratories' proactive adherence to disclosure norms.
Brooks Laboratories Limited
Brooks Laboratories Limited announced its board has approved the sale of 51,220 equity shares in Brooks Steriscience Limited. The shares will be sold to Steriscience Specialities Private Limited for a cash consideration of ₹20,760 per share. This transaction aggregates to approximately ₹106.33 crore, pending customary documentation and regulatory requirements. For investors, this represents a significant divestment by Brooks Laboratories, generating substantial cash flow which could be used for other strategic initiatives or strengthening its financial position.